NCT06899646View on ClinicalTrials.gov

EXOMIND (BTL-699-2) for Improvement of Mental Well-being

NACompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

July 8, 2024

Primary Completion Date

February 3, 2025

Study Completion Date

February 3, 2025

Conditions
Well-Being, Psychological
Interventions
DEVICE

Treatment with BTL-699-2

Four transcranial magnetic stimulation treatments with the BTL-699-2 device will be delivered over the left dorsolateral prefrontal cortex, spaced 5 to 10 days apart. The intensity will be adjusted according to the subject's feedback, up to 100% of the individual's motor threshold.

Trial Locations (3)

10022

Yael Halaas, M.D., F.A.C.S., New York

34787

Luxury Psychiatry Medical and Spa, Winter Garden

85296

Contour Medical, Gilbert

All Listed Sponsors
lead

BTL Industries Ltd.

INDUSTRY

NCT06899646 - EXOMIND (BTL-699-2) for Improvement of Mental Well-being | Biotech Hunter | Biotech Hunter